Primary Sj€ ogren syndrome (pSS) is characterized by chronic B-cell activation, leading to lymphoma, mainly non-Hodgkin lymphoma, involving the salivary glands and other mucosal extranodal sites in about 5% of patients with pSS during the course of the disease. 1 The pathophysiology of the disease remains unclear. 2 Usually, pSS is defined as a type 1 interferon-driven disease caused by increased expression of interferon-regulated genes in minor salivary gland biopsy specimens and PBMCs from patients with pSS. 3, 4 However, discriminating between a type 1 and type 2 interferon signature is difficult, and both interferons are involved in the pathophysiology of lupus, dermatomyositis, and pSS. [5] [6] [7] Moreover, interaction between type 1 and 2 interferons has been described, with type 2 interferons being able to act directly on human T cells to drive T H 1 cell development through an IFN-a/b receptor-mediated recruitment of signal transducer and activator of transcription 4 (STAT4). 8, 9 Thus IL-12, a STAT4-dependant cytokine, could be at the crossroads of both interferon types.
The well-known IL-12p70 protein is a noncovalent heterodimer formed by 2 subunits, IL-12p35 and IL-12p40, which is encoded by IL12A on chromosome 3 and IL12B on chromosome 5, respectively. 10, 11 The biological functions of human IL-12 are mediated by the heterodimeric IL-12 receptor (IL-12R), which is composed of 2 subunits, the b1 (IL-12Rb1) and b2 (IL-12Rb2) chains.
Recently, a genome-wide association study (GWAS) emphasized the role of IL-12 in pSS pathophysiology by finding a significant association between pSS and a single nucleotide polymorphism (SNP) within the IL12A locus (rs485497). Moreover, expression quantitative trait loci (eQTL) analyses revealed increased mRNA levels of IL12p35 among rs4680536*A allele carriers, assuming the functional consequences of this other SNP located in the same IL12A locus. 12 The IL-12p35 subunit is also shared by IL-35, another recently discovered cytokine of the IL-12 family with immunosuppressive and anti-inflammatory functions. [13] [14] [15] In mouse models IL-35, a heterodimer formed by the combination of IL-12p35 with the EBV-induced gene protein 3 (EBI-3) subunit, induces regulatory T (Treg) or regulatory B (Breg) lymphocytes during inflammation and could have effects on peripheral immune tolerance in human diseases. [16] [17] [18] In experimental models mice lacking expression of IL-35 subunits (IL-12p35 or EBI-3) in B cells had exacerbated experimental autoimmune encephalitis but greater protection against Salmonella species-induced sepsis. 19 IL-35, which induces Breg cell differentiation, can also be secreted in an autocrine manner. These IL- 35 1 Breg cells have a suppressive action through IL-10 secretion. 18 Tolerogenic dendritic cells are another relevant source of IL-35 in human subjects, as recently published. 20 Other animal models have illustrated the potential role of IL-12/IL-35 pathways in pSS pathophysiology. IL-12-transgenic mice have high serum levels of IL-12p70 and a Sj€ ogren-like syndrome, with dryness and lung-specific and salivary gland-specific damage, as well as anti-SSB antibodies. 21, 22 Mice with knockout for IL-12Rb2 (theoretically altering both IL-12 and IL-35 signaling) show lymphoepithelial lesions close to those observed during lymphoma transformation in salivary glands of patients with Sj€ ogren syndrome. 23 These observations might appear contradictory but could also be explained by the dual involvement of IL-12 and IL-35 in disease pathophysiology, considering that IL-35 can also signal through ''unconventional'' receptors, such as the homodimeric IL-12Rb2/IL-12Rb2 receptor, which activates only STAT4. 24 Therefore some of the pathogenic effects observed might be due to a dysfunctional IL-35 regulatory pathway.
In light of this recent evidence, we aimed to decipher the role of IL-12 and IL-35 in the pathophysiology of pSS.
METHODS

Study population
The genetic study involved 673 patients with a pSS diagnosis according to the American-European Consensus Group criteria 25 ; patients were from the national French prospective cohort Atteinte Syst emique et Evolution des patients atteints de Syndrome de Sj€ ogren primitive (ASSESS; principal investigator [PI]: X. Mariette and J. E. Gottenberg) cohort and an independent Paris-Sud University cohort (PI: X. Mariette) and were compared with 585 healthy control subjects (French blood donors). All patients and control subjects provided written informed consent. In total, 47 ancestry informative markers (AIMs) were used to identify genetic outliers and to adjust for population stratification (see the section on Statistical analysis).
Among these patients and control subjects, 262 (112 patients and 150 control subjects) were removed because of quality controls, missing data, or nonwhite origin based on genetic markers for ancestry (Fig 1 and see Fig E1, A, in this article's Online Repository at www.jacionline.org). The final study population assessed for genetic analyses and described in the Results section involved 561 patients with pSS and 435 healthy control subjects (see Fig E1,  A) . Active pSS was defined as a EULAR Sj€ ogren Syndrome Disease Activity Index (ESSDAI) score of 5 or greater. 26 The patients from the ASSESS cohort were also used for evaluating cytokine levels in serum.
IL12A locus genotyping
All patients and control subjects underwent genotyping for 13 SNPs of IL12A (see Table E1 in this article's Online Repository at www.jacionline.org) by using a competitive allele-specific PCR system (KASpar genotyping; an improved fluorescence resonance energy transfer method developed by LCGenomics, Hoddeston, United Kingdom; http://www.lgcgroup.com), as previously described. 27 All genotyped SNPs were assessed for deviation from Hardy-Weinberg equilibrium. The 13 SNPs were selected because they were previously associated with pSS in the GWAS 12 or with other autoimmune diseases. 13 Among the initial 673 patients and 585 control subjects, 74 subjects were excluded because AIM analysis suggested nonwhite ancestry and 32 self-reported nonwhite ancestry; 41 were excluded because of a genotyping call rate of less than 15%, 68 for failed genotyping across all analyzed SNPs, 8 for a rare variant that occurs in nonwhite subjects, and 39 for missing clinical data. Overall, data for 561 patients and 435 control subjects were used for genetic study of the IL12A locus (Fig 1 and see Fig E1, A) . An additional 1203 control subjects were assessed for the rs485497 replication study (see Fig E1, A) . In this last population AIMs were not available, but as surrogate information regarding white ancestry, each control subject had 4 grandparents born in France.
Functional studies in healthy control subjects
We focused our functional analyses on 2 relevant SNPs located within the IL12A locus: rs485497, the SNP most significantly associated with pSS in the J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 1 recent GWAS study, and rs4680536, which was significantly associated with high IL12 mRNA expression on eQTL analysis in the same work. 12 Patients and control subjects assessed for functional studies are depicted in Fig E1, B. In total, 17 healthy control subjects underwent sequencing for both SNPs (data not shown). Monocytes from all 17 healthy control subjects were stimulated in vitro, and differences were assessed according to genotype. Genomic DNA was extracted from peripheral blood samples (Qiagen, Courtaboeuf, France). PCR primers were designed by using Primer 3 to amplify segments of genomic DNA that included the exons and intron-exon boundaries to detect IL-12 locus variants. Sequencing was performed by using the Sanger method.
Isolation and culture of cells from healthy control subjects
PBMCs were isolated from the 17 healthy subjects by using density-gradient centrifugation. CD14 1 cells were isolated by means of direct magnetic labeling with CD14 Microbeads (Miltenyi Biotec, Paris, France), stained with CD14-allophycocyanin (BD Biosciences, Le pont de Claix, France), and analyzed by using the BD FACSCanto (BD Biosciences) and FlowJo software (TreeStar, Ashland, Ore). Isolated CD14 1 cells were cultured with LPS at 1 mg/mL and IFN-g at 1000 UI/mL for 2 or 48 hours in culture medium containing RPMI 1640 GlutaMAX (Gibco, Carlsbad, Calif) supplemented with 10% SVF (Dutscher, Brumath, France), penicillin (100 U/mL), streptomycin (100 mg/mL), HEPES buffer (10 mmol/L), pyruvate sodium (1 mmol/L), and amino acids (Invitrogen, Cergy Pontoise, France) at 2.5 3 10 5 cells per 500 mL in 48-well plates at 378C and 5% CO 2 . Supernatants were stored at 2808C, and cells were lysed for mRNA extraction.
Real-time PCR and quantitative RT-PCR
Total RNA was isolated from cells by using the RNeasy Mini kit (Qiagen). cDNA synthesis involved use of the Enhanced Avian HS RT-PCR kit (Sigma-Aldrich, Saint Quentin Fallavier, France). cDNA levels of IL12A and b-actin were analyzed by using LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics, Meylan, France) with Light Cycler-based kinetic qRT-PCR (Roche Diagnostics). Amplification involved the sequence primers for IL12A (forward: 59-CAG ACC CAG GAA TGT TCC CA -39 and reverse: 59-AGT TTG TCT GGC CTT CTG GAT -39) and b-actin (forward: 59-GCT GTG CTA CGT CGC CCT-39 and reverse: 59-AAG GTA GTT TGG TGG ATG CC-39). The final solution contained 1 mL of forward and reverse primers, 2 mL of cDNA, 2 mL of MasterMix, 1.6 or 1.2 mL of MgCl 2 for IL12A or b-actin, and H 2 O for a final volume of 20 mL. Each sample was processed in duplicates, with initial incubation at 958C for 10 minutes, followed by 35 cycles of 958C for 10 seconds, 628C for 5 seconds, and 728C for 7 seconds for IL12A and 40 cycles of 958C for 10 seconds, 638C for 10 seconds, and 728C for 15 seconds for b-actin. Variations in mRNA recovery and reverse transcription yield were normalized to those of b-actin as a housekeeping gene.
Protein quantification from culture supernatants and sera
Cytokine levels were evaluated in sera from 385 patients included in the ASSESS cohort (serum bank) and 50 healthy control subjects from the Vari et e cohort, a serum bank of 1000 healthy control subjects (PI: P. Chanson), and in culture supernatants. Patients and control subjects were age and sex matched. quantified by using an ELISA kit (Quantikine; BioLegend, San Diego, Calif) with no cross-reactivity with IL-12p70. IL-12p70 levels were quantified in supernatants (detection threshold, 0.625 pg/mL) from monocytes after 48 hours of culture by using a kit (hsQuantikine; R&D Systems, Minneapolis, Minn). Human IL-12p70 levels in sera from patients included in the ASSESS cohort (detection threshold, 1.25 pg/mL) was assessed by using Luminex technology (HTH17MAG-14K; Merck, Darmstadt, Germany), according to the manufacturer's instructions. All kits used to assess IL-12p70 serum levels are specific and have shown no cross-reactivity with IL-12p40. All cytokine concentrations were calculated by using Bio-Plex Manager 3.0 (Bio-Rad Laboratories, Hercules, Calif), with a 4-parameter curve-fitting algorithm used for standard curve calculations. ''High level of cytokine'' was defined as the upper quartile (Q4) of cytokine distribution (ie, >3.510 pg/mL for IL-12p70 and >6.163 ng/mL for IL-35).
RNA sequencing analysis
We sorted epithelial cells from salivary gland biopsy specimens and blood cellular subsets (CD4 1 and CD8 1 T cells and B lymphocytes) from patients with pSS and control subjects. mRNA was submitted to RNA sequencing (RNAseq) and then to transcriptomic analysis for quantifying IL12p35 and EBI3 mRNA. All these methods are presented in the Methods section in this article's Online Repository at www.jacionline.org.
Statistical analysis
To identify ancestry outliers and adjust for population structure, we used principal component analysis of 47 AIMs with EIGENSTRAT. 28 The IL12A haplotype was analyzed by using Haploview 4.2 (Broad Institute, Cambridge, Mass; Fig 2) . For case-control analyses, results were expressed as allelic frequencies. Comparison of clinical and biological characteristics of patients involved the Fisher exact test. Analysis of mRNA levels in terms of IL12A polymorphism or phenotype involved Kruskal-Wallis and Mann-Whitney nonparametric tests (GraphPad Software, La Jolla, Calif). The correlation between mRNA/protein levels of IL-12/IL-35 and B markers or type I interferon-induced genes involved the Spearman test. The association of cytokine level and phenotype was estimated by using the x 2 test. B-cell serum markers were assessed centrally and with blinding to clinical or biological data. P values of less than .05 were considered statistically significant.
RESULTS
Patients' characteristics
All patients fulfilled the American-European Consensus Group criteria. 24 The characteristics of all patients with pSS included in the study are summarized in Table I .
For genetic studies, 561 patients with pSS were assessed (Fig 1  and see Fig E1, A) . Briefly, 56% of patients were anti-SSA positive, 31% were anti-SSB positive, and 54% had systemic manifestations. At inclusion, 26 (5%) patients had a history of lymphoma.
The population included for functional analysis and assessment of cytokines levels in patients with pSS is part of the ASSESS cohort (see Fig E1, B) . Briefly, 94% of patients were women, the median age was 58 years, and median disease duration was 5 years; 59% of patients were anti-SSA positive, and 33% anti-SSB positive; 41% of patients were rheumatoid factor positive; and 65% of patients had active or past systemic involvement. The median ESSDAI score was 2, and 37% of patients had active disease with ESSDAI scores of 5 or greater.
Ninety-eight patients among the ASSESS cohort were selected for functional analyses, according to the availability of the sera (see Fig E1, B) . 
Replication of rs485497 association with pSS
We first aimed to replicate the previously reported genetic association 12 of the IL12A rs485497 SNP with pSS in 554 patients with pSS and 1634 control subjects. This polymorphism is located in the 39 untranslated region of the IL12A gene. We confirmed that rs485497 was significantly associated with pSS (odds ratio, 1.16; 95% confidence interval, 1.02-1.34; P 5 .028; Table II) .
We further analyzed 561 patients and 435 control subjects to screen 12 other SNPs located within the IL12A locus (see Table E1 ). None of these additional SNPs was significantly associated with pSS (data not shown), but subgroup analyses revealed 6 polymorphisms located at the 39 site or in the second intron of the IL12A locus significantly associated with pSS with anti-SSA autoantibodies (Table III) . We found no association between any of the studied SNPs and systemic manifestations or lymphoma or any association of the IL12A haplotype, including those carrying rs485497, with pSS (data not shown).
IL12A rs485497 is associated with increased serum protein levels of IL-12p70
We performed quantitative RT-PCR for IL-12p35 on PBMCs from 75 patients with pSS and found no statistical association between mRNA levels and rs485497 or rs485499 genotypes (P 5 .72 and P 5 .29, respectively; see Fig E2 in this article's Online Repository at www.jacionline.org).
However, rs485497*A carriers had higher protein levels of IL-12p70 than GG homozygous patients (12.5 6 36.32 vs 1.752 6 5.027 pg/mL, P 5 .016, Fig 3) . Neither rs485497 nor rs485499 genotypes affected serum IL-35 levels from patients with pSS (P 5 .19 and P 5 .46, see Fig E3 in this article's Online Repository at www.jacionline.org). We found no functional consequences for protein expression when considering IL12A haplotypes (data not shown).
To better define the functional consequences of rs485497 or rs485499, we aimed to assess whether these SNPs could modify the cellular response under cell stimulation. Monocytes from 17 healthy control subjects were stimulated with LPS plus IFN-g. After 2 hours of culture, IL12p35 mRNA was 15-fold increased but without any differences based on rs485497 or rs485499 genotypes. Similarly, supernatants harvested after 48 hours of culture showed no significant differences in IL-12p70 or IL-35 protein levels by rs485497 or rs485499 genotypes (data not shown).
IL-12 levels are greater in patients with pSS than healthy control subjects and associated with disease activity IL-12p70 levels were quantified in 36 patients with pSS and 34 healthy control subjects (see Fig E1, B) . The cytokine was quantifiable in sera from patients with pSS but was largely undetectable in healthy control subjects (quantifiable in 47% vs 6%, respectively; P 5 .0001). The mean IL-12p70 level differed between patients and control subjects (8.9 6 30 vs 1.3 6 7 pg/mL, P 5 .0001; Fig 4, A) . IL-12p70 levels were even more increased in patients with active disease defined by an ESSDAI score of 5 or greater (P 5.048; Fig 4, B) . We found no association with autoantibody status, disease duration, systemic manifestations, or lymphoma and no correlation with B-cell activation markers.
IL-35 levels are decreased in patients with pSS and might protect against systemic manifestations
To elucidate a potential role of IL-35 in patients with pSS, we quantified IL-35 protein levels in sera from 385 patients and 50 control subjects (see Fig E1, B) . The specificity of the IL-35 153 (41) 273 (59) 42 (20) Quantitative values are expressed as medians (25th-75th percentiles), unless otherwise specified. Systemic involvement involves past or present (at the time of enrollment) systemic manifestations. All percentage are calculated among patients with available data. ELISA kit was assessed with a personal positive control managed by Dr Odile Devergne. Four conditions were tested (blank, IL-35 standard from the kit, another source of IL-35 without the Fc portion and linker, and a recombinant EBI-3). IL-35 levels were detected for conditions 2 and 3. This result confirmed the specificity of the ELISA kit for IL-35 and the absence of cross-reactivity with EBI-3 or the Fc portion. Mean IL-35 serum levels were significantly lower in patients with pSS than in age-and sex-matched healthy control subjects (7.31 6 15 vs 8.66 6 14.8 ng/mL, P 5.0001; Fig 5, A) . Of note, 40% of patients with low IL-35 levels had active disease, as defined by an ESSDAI score of 5 or greater, compared with only 28% of those with high IL-35 levels (P 5 .05; Fig 5, B) . Similarly, 99% of patients with high IL-35 serum levels had no history of lymphoma compared with 93% of those with low IL-35 levels (P 5 .03; Fig 6, A) . Serum levels of IL-35 were lower among patients with than those without lymphoma, but the difference was not significant (Fig 6, B) . We did not find any association of serum IL-35 levels with other markers predictive of lymphoma (purpura, low C4 count, CD4 lymphopenia, B cell-activating factor of the TNF family [BAFF] serum levels, or rheumatoid factor).
We found a slight but significant correlation between IL-35 serum levels and some serum B-cell activation biomarkers,
Then we compared levels of EBI3 and IL12p35 transcripts through RNAseq in B lymphocytes and CD4 and CD8 T lymphocytes sorted from blood from 16 patients with pSS and 7 control subjects. Epithelial cells were sorted from salivary gland biopsy specimens from 9 patients with pSS and 4 control subjects. We found no expression of EBI3 in this later cell population (Fig  7) . In peripheral blood EBI3 and IL12p35 transcripts were both expressed in B lymphocytes, and the expression of these transcripts tended toward a lower level among patients with pSS compared with control subjects (although not statistically significant). IL12p35 transcript was ubiquitously expressed at a low level, whereas EBI3 transcript was not found in CD4
1 and CD8 1 cells. No differences were found between patients and control subjects concerning these last blood cell types.
DISCUSSION
This study demonstrates potential involvement of the IL-12/ IL-35 imbalance in patients with pSS. We confirmed the genetic association between rs485497 located within the IL12A locus and pSS and found a functional consequence of this SNP characterized by increased IL-12p70 protein levels in sera of rs485497*A carriers. IL-35 protein levels were lower in patients with pSS than healthy control subjects, which is in contrast to IL-12p70, which was highly expressed among patients with pSS. Within the entire cohort, serum IL-35 levels were associated with low disease activity and lower incidence of lymphoma in contrast to serum IL-12p70 levels, which were associated more with active disease.
pSS is a complex and heterogeneous autoimmune disease with genetic predisposition highlighted by 2 recent GWASs of white and Chinese patients, confirming previous data regarding the association with polymorphisms of human leukocyte antigen molecules, interferon regulatory factor 5 (IRF5), BLK, and STAT4. 12, [29] [30] [31] [32] [33] [34] Considering that the IL12A locus appeared for the first time in association with pSS, we aimed to confirm these results in an independent cohort of patients with pSS. In the present study we replicated the association of rs485497 and pSS. This association, even if statistically significant, was weak, which confirms the low effect size of this SNP for disease predisposition. Some additional SNPs assessed in our subgroup analysis were associated with autoantibody status and not the disease itself. Because this locus is involved in other autoimmune diseases (celiac disease, Graves disease, atopic dermatitis, multiple sclerosis, or primary biliary cirrhosis) 13 and considering that few functional studies have been performed, we aimed to define the consequences of some selected SNPs on protein and mRNA expression. We assessed the functional consequences of 2 specific SNPs: rs485497, which is significantly associated with pSS, and rs485499, which is in perfect linkage disequilibrium with rs4680536 (r 2 5 0.87, D9 5 0.99) that was associated with a high mRNA level in eQTL analysis in the previously published GWAS. 12 We hypothesized that in an inflammatory state these polymorphisms could lead to differential cytokine expression. Because LPS and IFN-g can enhance IL-12p70 35 and IL-35 production by monocytes or PBMCs, we used these stimuli on cell cultures. Unfortunately, at steady state or under stimulatory conditions, the genotypes did not affect IL-35 expression. However, patients with the at-risk allele rs485497*A had higher serum levels of IL-12p70 protein. We still do not know how this SNP, which is located at the 39 untranslated region of IL12A gene and out of a coding region, could act on IL-12p70 protein expression. Because rs485497 can promote IL-12p70 dimerization rather than production (no difference in IL-12p35 mRNA expression), we propose 2 possible explanations. The SNP might alter the seed sequence of the corresponding miR and lead to an increased expression of IL-12p70 or might enhance the affinity of IL-12p35 for IL-12p40 to the detriment of EBI-3, promoting dimerization of IL-12p70 rather than IL-35. This last hypothesis suggests that rs485497 is in complete linkage disequilibrium with another SNP located in coding area to affect the tridimensional structure of the protein.
Coexpression of IL-12p35 and IL-12p40 in the same cell is necessary to produce the disulfide-linked bioactive IL-12p70 cytokine. 35, 36 Thus the associated SNP might promote IL-12p70 formation rather than increased IL-12p35 production itself or IL-35 dimerization. Further functional studies are necessary to better understand these findings. Our data suggest that IL-12 could play a role in the pathophysiology of pSS. We showed that IL-12p70 levels are greater in sera of patients than healthy control subjects and are associated with active disease. Several arguments in the literature support a potential pathogenic role of IL-12 in different forms of Sj€ ogren syndrome. IL-12
1 cells infiltrate salivary glands of patients with pSS compared with healthy subjects. [37] [38] [39] [40] IL-12 induces polarization to the T H 1 phenotype and results in IFN-g secretion, particularly by T lymphocytes and natural killer cells, 41 a subset of cells recently found to play a role in the pathogenesis of pSS. 42 Increased serum IL-12 levels could be a marker of a type 2 interferon-associated disease. Manoussakis et al 39 described 2 distinct profiles of pSS in the salivary glands: IL-12-dominant lesions and IL-18-predominant infiltrates. Interestingly, this last profile featured low in situ IL-12 expression and was characterized by Sj€ ogren syndrome clinical manifestations and serologic profiles associated with high risk of lymphoma development. In sera patients with (Sj€ ogren syndrome germinal center
[SSGC]1) and without (SSGC2) germinal centers show distinctive distribution of cytokines. IL-12p40 and BAFF, among others, were identified as key discriminators between these subgroups, and their levels were inversely correlated. 43 Two subtypes of patients with pSS can be described: patients with high IL-12p40 levels and SSGC2 and patients with high BAFF levels and SSGC 1 with systemic manifestations that are prone to lymphoma. Finally, in the Belimumab in Subjects With Primary Sj€ ogren's Syndrome (BELISS) trial, good response was obtained exclusively in patients with low levels of natural killer cells in peripheral blood or the salivary glands. 44 These findings support the hypothesis of several forms of the disease. Patients with high levels of IL-12p70 in serum could have a T H 1 signature, have activation of natural killer cells both in blood and salivary glands, and be less sensitive to B cell-targeted therapy.
IL-35 is a newly identified member of the IL-12 cytokine family formed by heterodimerization of EBI-3 protein with the Fisher test) . B, IL-35 serum levels in patients with pSS with (n 5 21) and without (n 5 364) a history of lymphoma. IL-35 serum levels tend to be higher in patients without lymphoma than those with active or history of lymphoma (7.6 6 15.4 vs 1.5 6 2.8; P 5 .16, Student test).
FIG 7.
Levels of EBI3 and IL12p35 mRNA expression in sorted cells from patients with pSS and control subjects. Results are presented for 16 patients with pSS and 7 control subjects in CD19 1 blood lymphocytes (CD191 BL), CD4 1 blood lymphocytes (CD41 BL), and CD8 1 blood lymphocytes (CD81 BL). Epithelial cells from salivary gland biopsy specimens from 9 patients with pSS and 4 control subjects (Gl EPTH) were also assessed for transcript expression. Results are expressed in normalized counts corresponding to the number of reads.
IL-12p35 subunit. IL-35 suppresses effector T-cell proliferation, especially for T H 17 lymphocytes, and induces generation of a regulatory population of iTr35 cells depending on IL-10. Our knowledge of this cytokine is mostly from studies of various mouse autoimmunity models of inhibiting inflammation. [14] [15] [16] 45 However, its expression is complex and appears different between mice and human subjects. IL-35 is constitutively expressed by forkhead box protein 3-positive Treg cells in mice but is inducible in effector T cells and Treg cells in human subjects. 14, 46 IL-35 serum levels were lower in patients with inflammatory bowel disease, immune thrombocytopenia, rheumatoid arthritis, or systemic lupus erythematosus (SLE) than in healthy control subjects. Also, this level was negatively associated with disease activity, as defined by the SLE Disease Activity Index, or disease activity in 28 joints erythrocyte sedimentation rate in patients with SLE and rheumatoid arthritis, respectively. [47] [48] [49] [50] In the same way we found that patients with low levels of IL-35 had high disease activity, which suggests that this cytokine could induce better disease control. To our knowledge, this is the first study reporting an association between IL-35 levels and Sj€ ogren syndrome. More recently, our group recently showed that disease activity is an independent risk factor of lymphoma in patients with pSS. 51 Thus the protective effect of IL-35 on lymphoma we found could be in line with such findings.
To better understand how IL-35 can act in the pathophysiology of pSS, we tried to identify the relevant cellular source of this cytokine (eg, plasma cells or dendritic cells). We performed staining on salivary glands with an anti-EBI-3 mAb using immunohistochemistry. We found low and nonspecific staining not limited to plasma or dendritic cells (data not shown). We were not able to perform a double-staining with an anti-IL-12p35 antibody to assess which cell is the major source of the complete heterodimer cytokine. However, our group recently published a study demonstrating the presence of plasma cells within the salivary biopsy specimens of patients with pSS using mass cytometry. 52 Unfortunately, until now, it was not possible to adapt the anti-EBI-3 antibody to mass cytometry. Transcriptomic analysis of sorted cells from peripheral blood and salivary gland biopsy specimens from patients with pSS and control subjects allowed us to identify B lymphocytes as a probable source of IL-35. Expression of EBI3 and IL12p35 transcripts tended toward a lower level among patients with pSS compared with control subjects but without reaching a statistically significant threshold. This observation is in accordance with our results on IL-35 protein levels in sera from patients and control subjects and are consistent with the hypothesis that Breg lymphocytes could be a relevant source, even if not exclusive, of IL-35, with these cells being less functional in patients with the active forms of pSS.
These experiments highlight the potential role of regulatory cells in patients with pSS. Controversial results have been published concerning circulating Treg cells in patients with pSS. [53] [54] [55] [56] For 10 years, the concept of Breg cells emerged from diverse observations in autoimmune or infectious diseases. Some B cells are known to provide anti-inflammatory functions through secretion of IL-10, called B10 cells. [57] [58] [59] Recently, a new subset of Breg cells has been described: B cells producing IL-35.
18,19 IL-35 induces an IL-35 Breg cell subpopulation different from traditional B10 cells, requiring both IL-10 and IL-35 for its suppressive function. 18 In patients with pSS, CD24 hi CD27 1 cells, defined as Breg cell precursors, are decreased in number and less functional to induce Treg cells from naive T cells. 60 Our study suggests that this functional defect could be explained by decreased IL-35 expression. Considering the importance of B cells in pathophysiology, Breg cells could be of interest in patients with pSS. However, a consensual phenotype for these Breg cells is necessary for further research. 61 Interestingly, IL-12Rb2 knockout mice produced fewer Breg cells and showed severe uveitis and prelymphoma lesions in salivary glands. 23 Thus IL-35 could play an important role in preventing the occurrence of lymphoma. Finally, tolerogenic dendritic cells could also be relevant because of their tendency to induce Treg or Breg cells, suppress the Ro/La-specific T-cell response, and produce IL-35. 20, 62 The main limitation of our study is the lack of experiments on the target tissue. pSS is also called autoimmune epithelitis because of its propensity to affect exocrine glands with local inflammation, thereby leading to their destruction. Whether the observations in sera reflect what happens in the target organ is unclear. Evaluating the in situ expression of IL-12 and IL-35 and establishing a correlation with lymphocyte infiltration is of interest.
Another limitation to our study is the lack of sampling at different stages of the disease. In a mouse model of pSS, Yanagi et al 63 demonstrated a significant role of IL-10 and IL-12 in the early stage before disease onset. Further studies should be performed to monitor the kinetics of expression of both cytokines during the disease. Of note, at our point of analysis, we did not find any association between serum IL-35 and IL-12 levels or between serum levels of these cytokines and disease duration, as was previously reported for systemic sclerosis. 64 In conclusion, both IL-12 and IL-35 are involved in pSS, especially with more severe disease and lymphoma. pSS appeared to be a heterogeneous disease with different profiles of cytokine expression according to disease activity. Serum IL-35 levels were associated with low disease activity and lower incidence of lymphoma in contrast to serum IL-12p70 levels, which were associated more with active disease. These results underline the role of Breg cells in the disease, and IL-35 is of particular interest because of its capacity to induce both Treg and Breg cells. Further studies of pSS and Breg and plasma cells, as well as in animal models of autoimmune diseases, would help us determine whether this regulatory cytokine could be of interest for future therapeutic approaches. 
Key messages
d The IL12A rs485497 polymorphism is associated with pSS and induces a high protein level of IL-12p70 in sera.
d High serum protein levels of IL-12p70 occur, especially in patients with pSS with high disease activity.
d IL-35 protein levels are decreased in patients with pSS and can protect against lymphoma.
d In blood cellular subsets both IL12p35 and EBI3 mRNAs were detected only in B cells, with a trend toward lower levels among patients with pSS.
METHODS
Cell isolation
PBMCs were isolated by means of Ficoll gradient centrifugation from whole blood of 16 patients with pSS and 7 control subjects within 4 hours of blood draw (heparin tubes). Labial salivary gland biopsy specimens were obtained at the time of diagnosis from 9 patients with pSS and 4 control subjects. These new patients and control subjects were different from the patients included in the ASSESS cohort and control subjects from the VARIETE cohort used for the other experiments. All patients fulfilled American-European Consensus Group criteria of Sj€ ogren syndrome, and all control subjects had normal or subnormal salivary gland biopsy without any anti-SSA/SSB antibodies.
One to 2 glands were collected in Dulbecco modified Eagle medium (DMEM) supplemented with antibiotics, sodium pyruvate, nonessential amino acids, and glutamine. Glands were first minced with scissors and enzymatically digested at 378C under rotating agitation (100 rpm) in DMEM containing 232 U/mL collagenase II (Worthington Biochemical, Lakewood, NJ) and 8 U/mL DNAse I (Sigma). After 2 washes in calcium-and magnesium-free PBS containing 1 mmol/L EDTA, cellular aggregates were resuspended in 0.5 mL of TrypLE Express Enzyme (Gibco) and incubated for 2 minutes at 378C. Enzyme inactivation was achieved by means of dilution with 4 mL of DMEM and immediately followed by gentle pipetting with a P1000 to facilitate cell dissociation. The resulting cell suspension was washed twice with medium supplemented with 0.8 U/mL DNAse I.
Cell sorting
After isolation, cells were stained, as described above, by using 496-diamidino- 
RNA extraction
Samples were thawed on ice, and RNA extraction was performed according to the manufacturer's instructions with the following modifications. Extra sheath fluid from the sort was estimated based on the number of cells sorted into the tube, and an appropriate volume of 70% ethanol was added to the samples. Because of low yield of RNA expected for this type of sample, linear acrylamide (catalog no. AM952; Ambion, Thermo Fisher Scientific, Waltham, Mass) was diluted in extraction buffer to be spiked in to a final concentration of 20 ng/mL. Extracted samples were placed in PCR Plates (Eppendorf twin.tec LoBind, catalog no. 0030129512; Eppendorf, NY) to minimize sample absorption onto plastic. RNA QC was performed on the Agilent 2100 Bioanalyzer with the RNA 6000 Pico Kit (catalog no. 5067-1513; Agilent Technologies, Santa Clara, Calif). RNA quantity was measured by using the Quant-iT RiboGreen RNA Assay Kit (catalog no. R11490; Thermo Fisher Scientific, Waltham, Mass) on the SpectraMax M5 (Molecular Devices, Sunnyvale, Calif).
Library generation and sequencing
One hundred picograms of total RNA was used as input for cDNA preparation by using the SMART-Seq v4 Ultra Low Input RNA Kit (catalog no. 634892; Clontech, Mountain View, Calif). Universal Human Reference RNA was included in the experiment as a positive control, and nuclease-free water was used to dilute the samples as a negative control or nontemplate control. By using the concentrations derived from the RiboGreen assay (Thermo Fisher Scientific), a normalization plate was made with a final concentration of 10.53 pg/mL per sample. cDNA was prepared according to the manufacturer's instructions, except for the additional spike-in of 1 mL of diluted ERCC RNA Spike-In Mix (catalog no. 4456740; Thermo Fisher Scientific) in each sample. After subtracting the averaged concentration of the ERCC-spiked nontemplate control from the sample concentration from the bioanalyzer trace, cDNA samples were normalized to 125 pg in 5 
Statistical analysis
Paired reads were aligned to the human reference genome (V38.79) by using STAR (version 2.5.0c). We used summarize Overlaps from the R-Package GenomicAlignments E1,E2 to count reads per gene with the following parameters: mode5''Union'', singleEnd5FALSE, inter.feature5FALSE, ignore.strand5FALSE, and fragments5FALSE. Statistical analyses were performed with the DESeq2 package. E3 Specifically, we used estimateSizeFactors to estimate normalization factors. Results were then expressed in normalized read counts (calculated by using the median ratio method from the DESeq2 R-Bioconductor package).
E4
Comparison between gene expression levels in patients with Sj€ ogren syndrome and control subjects was performed after normalization of counts by using a nonparametric test (Mann-Whitney).
FIG E1.
Origin of the different populations studied. A, Different cohorts included in the genetic analysis. Six hundred seventy-three patients with pSS from 2 cohorts and 585 healthy control subjects were available for genetic assessment. Two hundred sixty-two subjects were removed from the analyses after several steps of quality control and ancestry assessments, leading to a final population of 561 patients with pSS and 435 healthy control subjects included in the genetic analysis. A third cohort of 1203 healthy control subjects was added for rs485497 assessment. B, Origin of the samples used for functional analysis. Proteins levels (IL-12p70 and IL-35) at baseline were quantified in sera of patients with pSS from the ASSESS cohort and in sera of healthy control subjects from the Vari et e cohort. Control subjects were age and sex matched to patients. IL12p35 mRNA expression at baseline was assessed on PBMCs from the ASSESS biobank. Monocytes from 17 healthy control subjects were cultured ex vivo and cytokine expression was measured in supernatants to understand the influence of genotype on cellular response. 
